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Abstract
Background: The use of prescription anti-obesity medication (AOM) is becoming increasingly common as
treatment options grow and become more accessible. However, AOM may not be without a wide range of
potentially negative impacts on patient functioning and well being. The Treatment Related Impact Measure (TRIM-
Weight) is an obesity treatment-specific patient reported outcomes (PRO) measure designed to assess the key
impacts of prescription anti-obesity medication. This paper will present the validation findings for the TRIM-Weight.
Methods: The online validation battery survey was administered in four countries (the U.S., U.K., Australia, and
Canada). Eligible subjects were over age eighteen, currently taking a prescription AOM and were currently or had
been obese during their life. Validation analyses were conducted according to an a priori statistical analysis plan.
Item level psychometric and conceptual criteria were used to refine and reduce the preliminary item pool and
factor analysis to identify structural domains was performed. Reliability and validity testing was then performed and
the minimally importance difference (MID) explored.
Results: Two hundred and eight subjects completed the survey. Twenty-one of the 43 items were dropped and a
five-factor structure was achieved: Daily Life, Weight Management, Treatment Burden, Experience of Side Effects,
and Psychological Health. A-priori criteria for internal consistency and test-retest coefficients for the total score and
all five subscales were met. All pre-specified hypotheses for convergent and known group validity were also met
with the exception of the domain of Daily Life (proven in an ad hoc analysis) as well as the 1/2 standard deviation
threshold for the MID.
Conclusion: The development and validation of the TRIM-Weight has been conducted according to well-defined
principles for the creation of a PRO measure. Based on the evidence to date, the TRIM-Weight can be considered a
brief, conceptually sound, valid and reliable PRO measure.
Introduction
The use of prescription anti-obesity medication (AOM)
to treat obesity is becoming increasingly common as
treatment options grow and become more accessible.
However, AOM has been associated with a wide range
of potentially negative impacts on patient functioning
and well being. Unfortunately, the impact of AOM is far
less well understood than the impact of obesity on
Health Related Quality of Life (HRQoL). The main chal-
lenge in understanding these impacts is the absence of a
conceptual and psychometrically sound treatment-speci-
fic measure to assess the full range of key impacts of
anti-obesity medication treatment on all aspects of
patients’ lives.
Patient-reported outcomes on weight management are
thus especially important since patients may use differ-
ent criteria than practitioners to assess treatment effi-
cacy with respect to weight loss, improvement in co-
morbidities and changes in quality of life. For example,
patients often have unrealistic expectations regarding
weight loss treatments, and may have a clinically signifi-
cant amount of weight loss, but remain dissatisfied [1,2].
Treatment satisfaction may be correlated with patient
compliance [3-5], impaired self-management [6], health
care decisions [7], and use of health care services [8]. It
is also associated with improvements in treatment effi-
cacy outcomes [9], and patients who are satisfied with
their treatments are more likely to maintain positive
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any medium, provided the original work is properly cited.physical and psychological health [10]. Therefore, asses-
sing treatment satisfaction can help the physician distin-
guish among treatment regimes with equal efficacy or
impact on HRQoL [11], as well as identify treatments
that patients find more acceptable [10], potentially
resulting in greater compliance and thereby efficacy.
Finally, both side effects and treatment burden seem to
d r i v em a n yo ft h en e g a t i ve impacts in the other
domains, resulting in poor treatment compliance, lead-
ing to further decreasing drug efficacy and treatment
satisfaction [5,12-14].
The Treatment Related Impact Measure (TRIM-
Weight) is an obesity treatment-specific patient reported
outcomes (PRO) measure designed to assess the key
impacts of prescription anti-obesity medication and be
applicable to the wide range of prescription medications
currently available [12,15]. The TRIM-Weight was
developed following the draft Food and Drug Adminis-
tration (FDA) guidelines for the development of patient
reported outcome (PRO) measures, including patient
focus groups and item generation based on a conceptual
model [16]. Treatment-specific measures, based on
input from clinical experts and patients with the condi-
tion of interest, are more targeted to a specific patient
population and incorporate only issues of relevance to
that population. In order to fully understand the impact
of AOM in obesity, data were collected from three
sources: literature, clinical experts, and respondents in
three countries (U.S., U.K. and France). Focus groups
were held in five cities in the three countries (Dallas,
Chicago, Los Angeles, London and Paris). Nine focus
groups were required to reach saturation of information,
both within and between countries, whereby no new
information was generated. A total of 70 eligible respon-
dents participated in the focus groups (29 men [11 U.S.,
10 U.K. and 8 France] and 41 women [25 U.S., 8 U.K.
and 8 France]). Analysis of the interview transcripts
identified five hypothesized domains that were most
impacted by AOM: Psychological Health, Daily Life,
Treatment Burden, Weight Management, and Experi-
ence of Side Effects and a theoretical model of the
impact of AOM on patient functioning and well-being
was developed (Figure 1).
Based on this theortetical model, and relying primar-
ily on the wording of impacts used by patients, items
were generated for each of the conceptual model
domains. These items then underwent cognitive
debriefing in an independent sample of obese adults
who were recruited and met the same eligibility cri-
teria as the interview sample to assess readability, com-
prehension of intended meaning, and relevance. A
validation ready version of the TRIM-Weight was then
developed. This paper will present the validation
findings for this obesity prescription AOM-specific
PRO measure, the TRIM-Weight.
Methods
Procedures
The debriefed version of the TRIM-Weight was incorpo-
rated into an online validation study to assess the mea-
surement and psychometric properties of the measure. As
with the development phase, the validation study metho-
dology closely followed the guidelines laid out by the FDA
for the development of a PRO measure [16]. Institutional
Review Board approval was obtained for the study and all
participants provided informed consent.
The validation battery survey was administered in
three countries (the U.S., Australia, and Canada) to a
sample independent of the development sample. Sub-
jects eligible for the study were over age eighteen, cur-
rently taking a prescription AOM and were either
currently or had been obese during their life (BMI
between 30 and 45). Two recruitment strategies were
employed to recruit the validation sample. The primary
strategy was to identify eligible subjects in the U.S., U.
K., Canada and Australia via a database of subjects who
had previously agreed to be contacted for research pur-
poses, managed by an academic unit of The University
of Syracuse. Eligibility was assessed online for the sam-
ple based on self-reported responses to screening ques-
tions. Those passing the screening questions were then
allowed into the survey. Additional participants were
recruited by an advertisement on Craig’s List, a U.S.
national network of online communities. For the Craig’s
List sample, those responding to the advertisement were
screened by telephone. Respondents who were eligible
and willing to participate were emailed the URL link to
access the validation survey and provided a unique ID
number. Regardless of recruitment strategy, all data
management and maintenance of the survey was con-
ducted by the first author.
Measures
In conjunction with the validation version of TRIM-
Weight, several additional measures were included in
the study and chosen for their comparative value for
this validation study, their high level of established valid-
ity, and brevity in their administration. These measures
include the following:
Center for Epidemiologic Studies Depression Scale (CES-D)
This measure includes twenty items comprising six scales
reflecting major dimensions of depression: depressed
mood, feelings of guilt and worthlessness, feelings of help-
lessness and hopelessness, psychomotor retardation, loss
of appetite, and sleep disturbance experienced in the past
week. Higher scores (both item and total scores) indicate
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higher on this scale suggests that the population under
study incurs a high risk for depression [17]. Introduced
and validated in 1977, this measure has been used exten-
sively as a research measure ever since. The original 1977
validation research for this measure demonstrated an
internal consistency ranging from .85 to .90 (coefficient
alpha and Spearman-Brown, split halves method) [17].
The test-retest reliability was in the moderate range for all
time intervals, ranging from .45 to .70, with the author’s
assessment of the “fairest” estimate of test retest reliability
as r = .54 [17].
Patient Health Questionnaire 15-Item Somatic Symptom
Severity Scale (PHQ-15)
This 15-item somatic symptom subscale of the Primary
Care Evaluation and Mental Disorders (PRIME-MD) is a
diagnostic instrument for common mental disorders.
Internal reliability is high, with a Cronbach’sa l p h ao f
.80 [18]. Convergent and discriminant validity was estab-
lished in a two-sample study comprising 6000 partici-
pants [18]. In a more recent study, the sensitivity (78%),
specificity (71%), and test-retest reliability (.60) estab-
lished the PHQ-15 as valid and “moderately reliable” in
detecting somatoform disorders [19]. The PHQ-15 mea-
sures somatic symptom severity [18].
The SF-12v2™ Health Survey
The SF-12v2 is a 12-item instrument for measuring
health status and outcomes from the patient’s point of
view in each of eight health concepts: physical function-
ing, role limitations due to physical health problems,
bodily pain, general health, vitality (energy/fatigue),
social functioning, role limitations due to emotional pro-
blems and mental health (psychological distress and psy-
chological well being). A high score indicates a more
favorable health state [20]. Derived from the longer SF-
36 Health Survey, the short form uses two of the longer
survey’s components, the Physical Component Summary
(PCS) and the Mental Component Summary (MCS).
The SF-12 demonstrates multiple R squares of 0.911 in
prediction of the SF-36 PCS and 0.918 in prediction of
the SF-36 MCS. In the general population, it achieved R
squares of 0.905 and 0.938 for the PCS and MCS,
respectively. Two-week test retest correlations of 0.89
were observed for the PCS and 0.76 for the MCS.
Furthermore, it has been validated for populations
beyond the United States [21]. Last, version 2 (the ver-
sion utilized in this study) is valid and demonstrates
high internal consistency reliability with alpha > 0.80
and a high test-retest reliability for the PCS of intraclass
correlation coefficient of 0.78. The MCS demonstrates a
Figure 1 Theoretical Model.
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coefficient of 0.60 [22].
Activity Impairment Assessment (AIA)
This five-item questionnaire assesses the amount of
time that an individual’s work or regular activities have
been impaired as a result of their condition. Responses
are provided in a 5-point Likert-type scale format, ran-
ging from “none of the time” to “all of the time,” and
given a score ranging from 0-4. The questionnaire is
scored for the total score [23]. The AIA has a high
level of internal consistency with Cronbach’sa l p h a=
0.93. It also has high levels of convergent validity (all
rs > 70), and divergent validity (rs = .078). Excellent
discriminant validity has been demonstrated in relation
to clinical evaluations [23].
Insulin Treatment Satisfaction Questionnaire (ITSQ)
The ITSQ is a 5 factor, 22-item questionnaire that dis-
cerns treatment satisfaction for diabetic patients who
are using insulin. In addition to an overall score, the
items comprise five domains: inconvenience of regi-
men, lifestyle flexibility, glycemic control, hypoglyce-
mic control, and insulin delivery device satisfaction. A
higher score indicates greater satisfaction with treat-
ment. Only the inconvenience of regimen domain,
which is not specific to diabetes, was used in this
study [10]. In total, the ITSQ demonstrates an internal
consistency (using Cronbach’s alpha coefficient) of the
subscales ranging from 0.79 to 0.91. Additionally, test-
retest reliability (using Spearman rank correlation coef-
ficients) ranged from 0.63 to 0.94. These scores show
moderate to high correlation with related measures of
treatment burden [10].
Treatment Satisfaction Questionnaire for Medication
(TSQM)
This is a fourteen-item questionnaire that measures a
patient’s experience with medication in terms of four
scales: side effects, effectiveness, convenience, and global
satisfaction. A higher score indicates greater satisfaction
with treatment [24]. In a validation study centered on a
variety of chronic diseases, factor analysis demonstrated
three factors (eigenvalues > 1.7) explaining 75.6% of
total variance. These factors, using Cronbach’sa l p h a
coefficient, ranged from 0.85 to 0.87. An additional fac-
tor analysis yielded a Global Satisfaction Scale which,
using Cronbach’s alpha coefficient, demonstrated a con-
sistency of 0.85 [24]. The TSQM-9 also demonstrates
good test-retest reliability with intraclass correlation
coefficients > 0.70 [25].
Frequency, Intensity, and Burden of Side Effects Rating
(FIBSER)
This three-item questionnaire measures medication side
effect impact over the past week using three domains:
frequency, intensity, and burden (the degree that medi-
cation interfered with day-to-day functions). The
FIBSER was shown to have high levels of internal con-
sistency with Cronbach’s alpha values ranging from 0.91
to 0.93 over multiple assessments of participants’ side
effects experiences [11]. The FIBSER was also shown to
be reliable (with high correlations between observations
made a short time apart), sustaining correlations at
Week 4 (with Week 2) of 0.46 (frequency), 0.48 (inten-
sity), and 0.45 (burden) [26]. The FIBSER has shown sig-
nificant construct validity (p < 0.0001) [26].
Quality of Life Enjoyment and Satisfaction Questionnaire
(Q-LES-Q) (Short Form)
Used widely to measure patient satisfaction pre- and
post- treatment, this 16-item questionnaire assesses the
degree of enjoyment and satisfaction experienced in
eight areas: physical health, subjective feelings of well
being, work, household duties, school, leisure, social
relationships, and general life quality. Scores are aggre-
gated, with higher scores indicative of greater enjoyment
or satisfaction in each domain [27]. In a 2007 study of
control volunteer subjects, the Q-LES-Q demonstrated
high internal consistency, with coefficients for each
domain ranging from 0.82 to 0.90. Intraclass coefficients
for these domains ranged from 0.58 to 0.89 [28].
Medication Compliance Scale (MCS)
A six item measure assessing how often a patient thinks
about postponing or skipping doses, or has actually
postponed or missed doses over the past two weeks.
Items are scored on a six-point Likert scale, from 0
(never) to 5 (always). The total score is calculated by
summing item values, with a higher score indicating
poorer compliance. This measure has not yet been vali-
dated [6]. Although this measure is currently not vali-
dated, it was chosen due to its high face validity and
proven ability to differentiate known groups in valida-
tion studies of other PRO measures [29].
Statistical Strategy
Validation analyses were conducted according to an a
priori developed statistical analysis plan (SAP). First,
item level psychometric and conceptual criteria were
used to refine and reduce the preliminary item pool
and reduce redundancy between items. Next, factor
analysis to identify structural domains was performed.
Reliability and validity testing were then performed.
To assess reliability, internal consistency and test-ret-
est reliability were examined. To assess validity, con-
tent and construct validity (convergent and known-
group) were examined. It is the intention of the devel-
opers that the TRIM-Weight can be used either as a
total score or that each domain could stand alone as a
separate measure. Therefore, all reliability and validity
tests were performed on both the total score and for
each domain. All data analyses were conducting using
SPSS [30].
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To assess item characteristics and the measurement
model (scaling) for the measure, the following tests were
performed:
Item reduction
For item reduction, both item psychometric properties
and conceptual importance were taken into considera-
tion in making retention/deletion decisions for the
initial item pool. Items were considered for deletion,
based on psychometric criteria, if the item had missing
data (i.e., no response) >5% of the time, if ceiling effects
were present (>50% optimal response) or if item-to-item
correlations within the total item pool were high, thus
indicating redundancy between items (Pearson’s correla-
tion coefficient >0.70) [31]. Items that did not perform
well psychometrically could be considered for retention
if conceptually important and/or unique, but were
otherwise dropped.
Factor structure
Factor structure was determined by an exploratory fac-
tor analysis using a Varimax orthogonal rotation with
Kaiser normalization. The number of factors was not
specified. Item-to-total scale correlations were assessed
using the Pearson’s correlation between individual item
scores and the total subscale score for the associated
subscale. Correlation coefficients < 0.40 were consid-
ered evidence of poor association [32]. The most
appropriate number of factors to be extracted was
determined by both the residual analysis, i.e., evalua-
tion of the ability of the factor solution to represent
the correlation structure, using 0.40 as the minimum
factor loading to be eligible as an item for a given fac-
tor, as well as taking into consideration the clinical
and theoretical interpretability of the solution. A scree
plot of the principle component solution was used as
guidance to the number of components with eigenva-
lues of greater than one.
To confirm the factor structures and to test the fit of
the domains, a confirmatory factor analysis was per-
formed using Mplus (Version 5.21). The Comparative
Fit Index (CFI) was examined for model fit with a
threshold of ≥ 0.90 indicating acceptable fit [33].
Reliability
Internal consistency reliability was examined using
Cronbach’s alpha statistics for the TRIM-Weight total
and subscale scores. An alpha of > 0.70 was considered
evidence of acceptable internal consistency [31,34].
Test-retest reliability was assessed at approximately
two weeks post initial completion of the battery. To be
eligible for the retest, participants had to respond “No”
to the questions: “Have you experienced any major life
events since you filled out the previous questionnaire
approximately 2 weeks ago (e.g., moving, divorce, losing
job)?” and “Has the past 2 weeks been an unusually
stressful period for you?” and respond “Yes” to the ques-
tion: “Have you been taking the same prescription
weight loss medication over the past 2 weeks?” Repro-
ducibility was assessed using the intraclass correlation
coefficient (ICC). An ICC of >0.70 was considered evi-
dence of acceptable test-retest reliability [31].
Convergent Validity
Convergent validity was evaluated by testing the follow-
ing a priori defined hypotheses using a two-tailed test at
a p < 0.05 level. When more than one hypothesis per
domain is proposed, the minimum threshold of one
hypothesis had to be met to claim convergent validity.
The hypotheses were:
H01: For the total score there will be a correlation
with Life Satisfaction (QLES) and/or the self-report
overall item.
H02: For the Psychological domain there will be a
correlation with Mental Health (SF-12) and/or the
self report overall Psychological Health item.
H03: For the Daily Life domain there will be a corre-
lation with Impairments in Activities (AIA) and/or
self report overall life impact item.
H04: For the Burden domain there will be a correla-
tion with Treatment Burden (TSQM domain) and
Inconvenience (ITSQ domain) and/or self report
overall item.
H05: For the Side Effects domain there will be a cor-
relation with Side Effect Frequency/Severity (FIB-
SER) and/or self report overall side effects item.
H06: For Efficacy (Weight Management) there will be
correlations with Treatment Efficacy (TSQM
domain) and/or self report overall efficacy item.
Criterion Validity
Criterion validity is a measure of how well one variable
or set of variables predicts an outcome. Criterion valid-
ity was tested by a priori hypotheses evaluating known-
group for each domain and the total score. The scores
of the groups on the TRIM-Weight domains were com-
pared using one-way ANOVA with groups as a fixed
factor. When more than one hypothesis per domain is
proposed, the minimum threshold of one hypothesis
had to be met to claim known-group validity. The
hypotheses were:
H07: For the total score, those with higher total score
will be more willing to stay on their AOM for a
greater period of time and/or be more compliant
with their AOM.
H08: For the Psychological domain, those with a
higher score will have less depression and/or self
report more supportive spouse/friends regarding
weight loss.
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f o rt h o s ew h ow o r ka n d / o rt h o s ew h oh a v el a r g e r
families.
H10: For the Burden domain, those who have to take
multiple tablets per day will have greater domain
scores.
H11: For the Side Effects domain, those with greater
somatization scores will have a greater domain score.
H12: For the Efficacy (Weight Management) domain,
those who report on average more weight loss per
length of time on drug will have greater efficacy.
Interpretability
To assess interpretability, the minimal important differ-
ence (MID) was examined. To calculate the MID, the
relationship and magnitude of change between these
self-report “overall” items to the scores of each TRIM-
Weight domain score were examined. The MIDs consid-
ered changes in scores of TRIM-Weight domains
between responses of “A little” and “Somewhat” as the
minimally important interval. For example, the differ-
ence in the mean response for the TRIM-Weight Bur-
den domain score for those who respond “A little” and
those who respond “Somewhat” on the independent
item: “Overall, how inconvenient is your weight loss
medication?” was calculated. For the total score, the dif-
ference between the “No impact at all” and “Slightly
positive impact” response categories was examined.
One-half standard deviation was considered the thresh-
old difference for the MID.
Results
Item Generation and Cognitive Debriefing
The items were generated based on the conceptual
model and worded to closely match patient statements.
Examples of patient statements and corresponding items
per domain are shown below. These items then under-
went cognitive debriefing. Four iterations (three blocks
of three participants and one block of two for a total of
eleven adults, four men and seven women) were
required to refine the items in terms of readability, rele-
vance, and formatting and reach consensus in an entire
block. As a result of the cognitive debriefing, a 43-item
TRIM-Weight was generated.
Validation Study
Sample
Via the primary strategy to find eligible subjects a total
of 195 subjects entered the Study Response survey por-
tal for the online validation survey; two subjects did not
Table 1 Validation Study Sample Description
Demographics Characteristics Total N = 208
GENDER
- Female 163 (78.4%)
- Male 44 (21.2%)
AGE (Years):
- Mean (Std. Deviation) 38.2 (10.3) years
- Range 20-76 years
Weight* (current, in kg [lbs]):
- Mean (Std. Deviation) 91.1 [200.8] (42.2)
- Range 54 [120]-147 [325]
BMI (at highest weight):
- Mean (Std. Deviation) 36.4 (4.4)
- Range 30-45
TYPE OF OAM MEDICATION (% of sample)
Phentermine 43.3%
Phendimetrazine 3.8%
Sibutramine 22.1%
Diethylpropion 3.4%
Orlistat 23.1%
Other/Missing 4.4%
EDUCATION:
- Less than or Completed High School or GED 84 (41.61%)
- College Degree (Associate’s Degree or B.A.) 96 (47.5%)
- Graduate Degree (or higher) 22 (10.9%)
ETHNICITY:
- White/Caucasian 168 (83.2%)
- Black/African American 14 (6.9%)
- Latino/Hispanic/Mexican American 10 (5.0%)
- Native American/Alaskan Native 1 (0.5%)
- Asian American/Pacific Islander 5 (2.5%)
- Mixed Racial Background 2 (1.0%)
- Other Races 2 (1.0%)
CURRENT LIVING ARRANGEMENT:
- Living with a spouse (% Yes) 169 (81.3%)
- Do you have children (% Yes) 50 (24.0%)
EMPLOYMENT:
- Full-time paid position 119 (59.8%)
- Part-time paid position 23 (11.6%)
- Not currently working for pay 47 (23.6%)
- Student 10 (5.0%)
HOUSEHOLD INCOME
- Less than $20,000 15 (7.4%)
- $20,000 to $39,999 32 (15.8%)
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from the survey. Thirty-two subjects agreed to complete
the survey, but did not meet BMI eligibility require-
ments. Of the remaining 161 subjects, ten were not eli-
gible, as they were not currently taking a prescription an
anti-obesity medication. Finally, one subject stopped
answering the items before getting to the TRIM-Weight
items. From the second strategy, a total of fifty-nine
subjects entered the Craig’s List survey portal; only one
did not answer any questions, leaving a total of fifty-
eight completed surveys. The combined final sample for
validating the TRIM-Weight was comprised of 208 sub-
jects and is shown in Table 1.
Analysis
Item reductionTwenty-one of the 43 items were
dropped due to redundancy with other items, ceiling
effects, poor factor loadings and/or did not fit concep-
tually with other items in the domain or did not tap
highly relevant concepts based on patient reported
information collected in the development phase. This
resulted in a 22-item measure, which was used for the
remaining analyses.
Factor structureAs hypothesized in the SAP, a five-fac-
tor structure, reflecting the hypothesized domains, was
achieved with six items making up the Daily Life
domain (component regression coefficients range .608 -
.796): three items in Weight Management (component
regression coefficients range .729 - .805), four items in
Treatment Burden (component regression coefficients
range .646 - .729), five items in Experience of Side
Effects (component regression coefficients range .475 -
.758), and four items making up the Psychological
Health domain (component regression coefficients range
.661 - .776). The scree plot confirmed five factors with
eigenvalues of greater than one.
The domains were confirmed with CFI values all
above 0.90: Daily Life, 0.977; Weight Management,
1.000; Treatment Burden, 0.996; Side Effects, 0.961; Psy-
chological, 1.000; and Total, 0.930.
ReliabilityAs seen in Table 2, internal consistency, as
measured by Cronbach’s alpha of the TRIM-Weight
Total score and all five subscales ranged between 0.71
and 0.94. The ICC values for test-retest reliability ran-
g e df r o m0 . 7 5t o0 . 8 6 .T h i sm e tt h eap r i o r ih y p o t h e s e s
regarding internal consistency and reproducibility.
Convergent ValidityAll pre-specified hypotheses were
met at p < 0.001. The Total TRIM-Weight significantly
correlated (r = 0.62) with the overall life satisfaction
scale of the Q-LES-Q and the Psychological Health sub-
scale (TRIM-Weight) had a significant association with
the SF-12 mental component summary (r = 0.60). The
Daily Life subscale correlated significantly with the AIA
total score (r = 0.74), while the Treatment Burden sub-
scale had a correlation of 0.70 with the TSQM-Burden.
Finally, predictions were met regarding strong correla-
tions between the Experience of Side Effects subscale
and the FIBSER total score (0.74).
Significant correlations were found between all of the
self-report overall items and their respective domains or
total score. Specifically, the TRIM-Weight Total score
was significantly correlated with the item “Overall, how
much of an impact has your weight loss medication had
on your life?” (r = 0.43). The Daily Life domain was sig-
nificantly correlated with the item “Overall, how much
does your weight loss medication impact your daily life?”
(r = 0.47). For the Weight Management domain, there
was a significant correlation with the item “Overall, how
well does your weight loss medication work?"(r = 0.63).
The Treatment Burden domain was significantly corre-
lated with the item “Overall, how convenient is your
weight loss medication?” (r = 0.64). There were also sig-
nificant correlations for the Side Effects domain with the
item “Overall, how much do side effects from your
weight loss medication negatively impact you?” (r = 0.68)
and for the Psychological Health domain with the item
“Overall, how much does your weight loss medication
negatively impact your psychological health?"(r = 0.55).
Criterion ValidityThe specified ap r i o r itests for
known-group validity were met for the total score and
all domains, with the exception of the domain of Daily
Life, which was proven in an ad hoc analysis. The total
Table 2 Reliability Statistics on the TRIM-Weight
TRIM-Weight
Domain
Internal Consistency Reliability
(Cronbach’s alpha)
Test-Retest
Reliability N = 75
(ICC)
TRIM-Weight
Total
0.9389 0.8554
Daily Life 0.9199 0.7588
Weight
Management
0.7076 0.7527
Treatment
Burden
0.7496 0.7699
Experience of
Side Effects
0.8829 0.7554
Psychological
Health
0.8799 0.7798
Table 1: Validation Study Sample Description (Continued)
- $40,000 to $59,999 45 (22.3%)
- $60,000 to $79,999 50 (24.8%)
- $80,000 to $99,999 29 (14.4%)
- $100,000 and over 30 (14.9%)
- Declined to answer 1 (0.5%)
1 One observation missing
2 One observation was deleted as out of range.
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likely or not likely to recommend their current treat-
ment to a friend (F = 26.69, p < 0.001). There was also
a significant difference between those compliant versus
those not being compliant with their treatment (F =
52.60, p < 0.001). The total TRIM-Weight was not able
to discriminate the length of time willing to stay on the
current treatment, as this was likely confounded by how
long the patients had already been on their treatment.
The Psychological Health subscale was able to discrimi-
nate between depression severity (F = 77.41, p < 0.001)
and level of social support from both family (F = 2.29, p
< 0.05) and friends (F = 4.43, p < 0.05). The Treatment
Burden subscale significantly differentiated treatment
f r e q u e n c yc o d e da so n et i m ead a y ,t w i c ead a y ,a n d3 +
times a day (F = 10.5, p < 0.001) and the Experience of
Side Effect subscale distinguished between severity of
somatization (F = 66.7, p < 0.001). The Weight Manage-
ment subscale differentiated between weight loss groups
(F = 9.8, p < 0.001). The Daily Life domain was not able
to discriminate between having children or working sta-
tus. This may be due to other factors, which overshadow
the impact of children or work on daily life, such as
stress. In a post-hoc analysis, the Daily Life domain was
able to significantly differentiate based on degree of
stress, which may be a more appropriate known group
(F = 6.26, p < 0.01).
InterpretabilityThe total score and all domains met
the MID threshold of 1/2 SD criteria as follows: Total
(Δ =8 . 5 ,1 / 2S D=7 . 2 ) ;W e i g h tM a n a g e m e n t( Δ =
11.6, 1/2 SD = 7.0); Treatment Burden (Δ = 13.1, 1/2
SD = 7.2); Experience of Side Effects (Δ = 14.6, 1/2 SD
= 8.4); Psychological Health (Δ = 10.3, 1/2 SD = 10.4);
and Daily Life (Δ = 16.1, 1/2 SD = 7.6) as shown in
Table 3.
Finally, exploratory regression analyses were per-
formed independently for each of the following variables
on the TRIM-Weight Total Score: BMI category, gen-
der, age and educational level. No significant relation-
ships were found. When all variables were examined
together in a final regression, gender was found to be
significant (p < .000) with the impact of OAM being
greater for women.
Final Measure
The validation process resulted in a 22-item TRIM-
Weight. The conceptual framework identifying the rela-
tionship between items, domains, and the overall con-
cept of the impact of prescription anti-obesity
medications is shown in Figure 2.
Response burden was imputed from the respondent
recorded time to complete the 43-item version TRIM-
Weight of 6.60 (SD = 4.86) minutes. Total time was
divided by 43 for a “per item time” and then the “per
item time” was multiplied by 22. Thus, the time for
completion of the 22-item TRIM-Weight is estimated at
3.38 (SD 2.49) minutes.
Discussion
Patient reported outcomes can be understood either
according to the broad stroke umbrella concept or as
Table 3 Minimal Important Difference of the TRIM-Weight
Mean N Mean N Difference 1/2 SD
TRIM-Weight Domain A little Somewhat
Overall, how much does your weight loss medication impact your daily life?
Daily Life 79.2 (15.2) 62 63.1 (21.9) 45 16.1 7.6
Overall, how well does your weight loss medication work? (reverse)
A little Somewhat
Weight Management 35.4 (15.5) 20 47.0 (13.9) 64 11.6 7.0
Overall, how convenient is your weight loss medication? (reverse)
A little Somewhat
Treatment Burden 41.7 (15.4) 15 54.8 (14.4) 38 13.1 7.2
Overall, how much do side effects from your weight loss medication negatively impact you?
A little Somewhat
Experience of Side Effects 66.3 (16.7) 59 51.7 (18.3) 45 14.6 8.4
Overall, how much does your weight loss medication negatively impact your psychological health?
A little Somewhat
Psychological Health 60.3 (20.9) 45 50.0 (20.4) 36 10.3 10.5
Overall, how well does your weight loss medication work?
No impact at all Slightly positive impact
TRIM-Weight Total 63.9 (21.1) 24 72.4 (14.4) 63 8.5 7.2
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are valid dimensions of a PRO measure and the appro-
priateness of the total versus the domain score is depen-
dent upon the purpose for which the measure is being
used. Therefore, the SAP for the TRIM-Weight was spe-
cifically written to validate the psychometric properties
of both the total as well as domain subscale scores and
the data from the validation study supports the claims
for reliability and validity for both. As a result, each
domain subscale can be used independently if assess-
ment of that specific concept alone is required.
The conceptual model and the 5 domains impacted by
AOM supported the TRIM-Weight item generation
were developed based on direct patient input collected
from focus groups and individual interviews. Each of
these domains labelled Daily Life, Psychological Health,
Weight Management, Treatment Burden and Experience
of Side Effects are critical components of how patients
experience AOM and are supported by previous
research which has identified ways in which being over-
weight or obese adversely affects daily life and psycholo-
gical health, including work productivity, attendance,
social integration, overall psychological well being, stig-
matization, self-esteem, joint pains, and depression
[1,35]. In contrast, weight loss has led to increased parti-
cipation in physical and social activities; greater energy
and vitality; improvements in mood, self-confidence,
self-concept, satisfaction with self-appearance and body
image; decreased mirror avoidance; and improvements
in emotional reaction, psychological stress, anxiety and
depression [36-39].
The validation study was conducted via the web,
which raises some potential bias in the sample selection
for the study. However, we believe the bias introduced
by a web-based study to be minimal, given the preva-
lence of computer access now available in the U.S., U.K.,
Canada and Australia. Also potentially biasing was the
self-reported eligibility requirement of BMI and current
AOM use. Given the minimal nature of the incentive to
participate in the study, the fact that Survey Response
subjects were pre-screened for eligibility before knowing
the exact nature of the study and that Craig’s List sub-
jects were screened by telephone, we believe this bias
was also not significant. The online format of the
TRIM-Weight was exactly the same as a paper and pen-
cil version, thus also suggesting that the two versions
would be equivalent in psychometric properties [40-42].
Validation is an iterative process and future work should
include the examination of psychometric properties in a
placebo double blind trial design. Additionally, examin-
ing responsiveness using change in clinical parameters
over time would be prudent.
As there were no longitudinal data available to fully
examine the MID based on change over time, self-report
items, one per domain of the TRIM-Weight, were used
as anchors to approximate the MID. This analysis was
considered exploratory and meant to provide prelimin-
ary estimates of differences established using an anchor-
Figure 2 Conceptual Framework.
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Page 9 of 11based approach. Since longitudinal data are not being
used, one must be cautious in the interpretation of the
results in relation to minimally important differences.
As these findings should be considered preliminary, they
s h o u l dn o tb eu s e da sa ne s t i m a t i o no ft h eM I D .H o w -
ever, they do indicate that an MID of 1/2 SD should be
achievable for the TRIM-Weight.
The development of a PRO is an iterative process and
as i n g l eP R Om a yt r u l yn e v e rb ev a l i d a t e df o ra l lp o s s i -
ble uses. The goal of this first validation study was to
determine the initial measurement model and funda-
mental reliability and validity of the TRIM-Weight. The
cross sectional and web based nature of the study
imposed certain limitations on the analyses which could
be conducted. Future research examining criterion valid-
ity of the TRIM-Weight using clinical parameters, longi-
tudinal data examining sensitivity to change and
interpretability as well as scaling properties, and a con-
firmatory factor analysis derived from clinical trial data
will be important next steps in the validation process.
Based on the clear negative impacts of AOM reported
by the patients, it is evident that newer treatments that
can reduce either the frequency or length of weight loss
plateaus, continue to work over extended periods of
time and allow for more consistent and long term
weight loss without debilitating side effects, are needed.
Improved understanding and assessment of the full
range of these impacts on multiple dimensions of func-
tioning and well-being will allow clinicians to realisti-
cally prepare patients for weight loss treatments,
monitor impacts over time and adjust medications as
needed to improve compliance.
Conclusion
The development and validation of the Treatment
Related Impact Measure-Weight (TRIM-Weight) has
been conducted according to well-defined scientific
principles for the creation of a PRO measure. Based on
t h ee v i d e n c et od a t e ,i ti ss u g g e s t e dt h a tt h eT R I M -
Weight Total score, as well as each domain subscale,
can be considered a brief, conceptually sound, rigorously
developed PRO measure with strong evidence support-
ing the psychometric properties.
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